De-risking a PD-L1 Targeting T-cell Engager with Preclinical Mouse Models

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

genO‑panhCD3 (humanized ε, δ and γ chains - hCD3edg) immunocompetent mice enable the in vivo efficacy and safety assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

‍